title: The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment.
abstract: In vitro, ribavirin acts as a lethal mutagen in Hantaan virus (HTNV)-infected Vero E6 cells, resulting in an increased mutation load and viral population extinction. In this study, we asked whether ribavirin treatment in the lethal, suckling mouse model of HTNV infection would act similarly. The HTNV genomic RNA (vRNA) copy number and infectious virus were measured in lungs of untreated and ribavirin-treated mice. In untreated, HTNV-infected mice, the vRNA copy number increased for 10 days postinfection (dpi) and thereafter remained constant through 26 dpi. Surprisingly, in ribavirin-treated, HTNV-infected mice, vRNA levels were similar to those in untreated mice between 10 and 26 dpi. Infectious virus levels, however, were different: in ribavirin-treated mice, the amount of infectious HTNV was significantly decreased relative to that in untreated mice, suggesting that ribavirin reduced the specific infectivity of the virus (amount of infectious virus produced per vRNA copy). Mutational analysis revealed a ribavirin-associated elevation in mutation frequency in HTNV vRNA similar to that previously reported in vitro. Codon-based analyses of rates of nonsynonymous (dN) and synonymous (dS) substitutions in the S segment revealed a positive selection for codons within the HTNV N protein gene in the ribavirin-treated vRNA population. In contrast, the vRNA population in untreated, HTNV-infected mice showed a lower level of diversity, reflecting purifying selection for the wild-type genome. In summary, these experiments show two different evolutionary paths that Hantavirus may take during infection in a lethal murine model of disease, as well as the importance of the in vivo host environment in the evolution of the virus, which was not apparent in our prior in vitro model system.
authors.affiliation: Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
authors.forename: Dong-Hoon
authors.initials: DH
authors.lastname: Chung
authors.forename: Åke
authors.initials: Å
authors.lastname: Västermark
authors.forename: Jeremy V
authors.initials: JV
authors.lastname: Camp
authors.forename: Ryan
authors.initials: R
authors.lastname: McAllister
authors.forename: Susanna K
authors.initials: SK
authors.lastname: Remold
authors.forename: Yong-Kyu
authors.initials: YK
authors.lastname: Chu
authors.forename: Carl
authors.initials: C
authors.lastname: Bruder
authors.forename: Colleen B
authors.initials: CB
authors.lastname: Jonsson
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000998:Antiviral Agents / Q000008:administration & dosage*; D004252:DNA Mutational Analysis; D004195:Disease Models, Animal; D019143:Evolution, Molecular; D005260:Female; D018063:Hantaan virus / Q000235:genetics* / Q000302:isolation & purification; D006480:Hemorrhagic Fever with Renal Syndrome / Q000188:drug therapy / Q000821:virology*; D008168:Lung / Q000821:virology; D051379:Mice; D008813:Mice, Inbred ICR; D059645:Mutation Rate; D011247:Pregnancy; D012367:RNA, Viral / Q000235:genetics*; D012254:Ribavirin / Q000008:administration & dosage*; D017422:Sequence Analysis, DNA; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin
references.citation: J Virol. 2005 Feb;79(3):1943-7
references.pmid: 15650220
references.citation: J Virol. 2009 Jun;83(11):5760-4
references.pmid: 19321623
references.citation: Bioinformatics. 2010 Oct 1;26(19):2455-7
references.pmid: 20671151
references.citation: Antimicrob Agents Chemother. 1989 Oct;33(10):1668-73
references.pmid: 2556073
references.citation: BioDrugs. 2003;17(3):169-77
references.pmid: 12749753
references.citation: J Virol. 2002 Aug;76(15):7587-94
references.pmid: 12097572
references.citation: Antimicrob Agents Chemother. 1986 Jun;29(6):1010-6
references.pmid: 3015012
references.citation: J Infect Dis. 1991 Dec;164(6):1119-27
references.pmid: 1683355
references.citation: Clin Infect Dis. 2004 Nov 1;39(9):1307-13
references.pmid: 15494907
references.citation: Bioinformatics. 2005 May 15;21(10):2531-3
references.pmid: 15713735
references.citation: PLoS One. 2012;7(6):e39941
references.pmid: 22761933
references.citation: J Virol. 2012 Mar;86(5):2869-73
references.pmid: 22190724
references.citation: Antiviral Res. 2012 Sep;95(3):282-92
references.pmid: 22705798
references.citation: Virology. 1981 Apr 30;110(2):281-9
references.pmid: 6111860
references.citation: Annu Rev Microbiol. 2004;58:183-205
references.pmid: 15487935
references.citation: Antimicrob Agents Chemother. 1977 Jun;11(6):946-51
references.pmid: 879760
references.citation: Virology. 2002 Jul 5;298(2):175-80
references.pmid: 12127780
references.citation: J Virol. 2005 Aug;79(15):10032-9
references.pmid: 16014963
references.citation: Am J Trop Med Hyg. 1998 Jul;59(1):58-65
references.pmid: 9684629
references.citation: Nature. 2006 Jan 19;439(7074):344-8
references.pmid: 16327776
references.citation: Virology. 2010 Jun 5;401(2):165-78
references.pmid: 20227103
references.citation: Antimicrob Agents Chemother. 2007 Jan;51(1):84-8
references.pmid: 17060520
references.citation: Annu Rev Med. 1999;50:531-45
references.pmid: 10073292
references.citation: J Virol. 2000 Oct;74(19):9245-55
references.pmid: 10982372
references.citation: Virology. 2001 Oct 10;289(1):6-14
references.pmid: 11601912
references.citation: Mol Biol Evol. 2005 May;22(5):1208-22
references.pmid: 15703242
references.citation: Virus Res. 2003 Dec;98(1):83-91
references.pmid: 14609633
references.citation: Arch Virol. 1985;84(3-4):197-206
references.pmid: 2859845
references.citation: Clin Microbiol Rev. 2010 Apr;23(2):412-41
references.pmid: 20375360
references.citation: Mol Biol Evol. 2011 Oct;28(10):2731-9
references.pmid: 21546353
references.citation: Antiviral Res. 2008 Jul;79(1):19-27
references.pmid: 18394724
references.citation: J Virol. 1999 Jul;73(7):5301-8
references.pmid: 10364276
references.citation: Virus Res. 2005 Feb;107(2):173-81
references.pmid: 15649563
references.citation: Emerg Infect Dis. 1997 Apr-Jun;3(2):95-104
references.pmid: 9204290
references.citation: PLoS One. 2011;6(8):e23560
references.pmid: 21853152
references.citation: J Virol. 2003 Jan;77(1):481-8
references.pmid: 12477853
references.citation: Antiviral Res. 1985 Feb;5(1):39-48
references.pmid: 3985607
references.citation: J Infect Dis. 1983 Dec;148(6):1005-12
references.pmid: 6140290
references.citation: Immunology. 2012 Nov;137(3):259-70
references.pmid: 22891772
references.citation: Antivir Chem Chemother. 2001 Sep;12(5):261-72
references.pmid: 11900345
references.citation: J Infect Dis. 1986 Mar;153(3):489-97
references.pmid: 2869089
references.citation: Nat Med. 2000 Dec;6(12):1375-9
references.pmid: 11100123
references.citation: Jpn J Vet Res. 2004 Feb;51(3-4):143-9
references.pmid: 15070039
references.citation: J Virol. 2007 Mar;81(6):2930-9
references.pmid: 17202214
references.citation: J Virol. 2007 Nov;81(21):11722-9
references.pmid: 17699579
references.citation: Antiviral Res. 2009 Jan;81(1):68-76
references.pmid: 18977392
references.citation: Virology. 2006 Mar 30;347(1):208-16
references.pmid: 16378630
references.citation: J Mol Med (Berl). 2002 Feb;80(2):86-95
references.pmid: 11907645
references.citation: PLoS Genet. 2012;8(7):e1002764
references.pmid: 22807683
references.citation: Rev Med Virol. 2006 Jan-Feb;16(1):37-48
references.pmid: 16287208
references.citation: Virus Res. 2005 Feb;107(2):195-205
references.pmid: 15649565
references.citation: J Virol. 1994 May;68(5):3000-6
references.pmid: 7512156
references.citation: Mol Biol Evol. 1993 May;10(3):512-26
references.pmid: 8336541
references.citation: Virus Res. 2003 Mar;92(1):37-45
references.pmid: 12606074
references.citation: Biochem Biophys Res Commun. 1979 Aug 13;89(3):830-6
references.pmid: 226095
references.citation: J Gen Virol. 2002 Apr;83(Pt 4):759-766
references.pmid: 11907324
references.citation: Antivir Ther. 1999;4(4):211-9
references.pmid: 10723500
references.citation: J Virol. 1994 Dec;68(12):7833-9
references.pmid: 7966573
references.citation: Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E86-93
references.pmid: 19751407
references.citation: Drug Resist Updat. 2004 Feb;7(1):19-24
references.pmid: 15072768
references.citation: Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900
references.pmid: 11371613
references.citation: J Hepatol. 1999 Mar;30(3):376-82
references.pmid: 10190717
references.citation: Virology. 1986 Dec;155(2):633-43
references.pmid: 3024404